Is VUG a Good ETF to Buy?
For the last few years, earnings growth from the tech…
Buy
64
AZNCF Quote, Financials, Valuation and Earnings
Last price:
$149.40
Seasonality move
:
9.19%
Day range:
$154.22 - $154.22
52-week range:
$120.64 - $175.00
Dividend yield:
2.01%
P/E ratio:
34.20x
P/S ratio:
4.45x
P/B ratio:
5.87x
Volume:
--
Avg. volume:
1.7K
1-year change:
15.63%
Market cap:
$239.1B
Revenue:
$54.1B
EPS (TTM):
$4.51
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, AstraZeneca PLC has -- downside to fair value with a price target of -- per share.
AZNCF vs. S&P 500
-
Over the past 5 trading days, AstraZeneca PLC has overperformed the S&P 500 by 3.7% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
AstraZeneca PLC does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
AstraZeneca PLC has grown year-over-year revenues for 7 quarters straight. In the most recent quarter AstraZeneca PLC reported revenues of $14.9B.
Earnings Growth
-
AstraZeneca PLC has grown year-over-year earnings for 5 quarters straight. In the most recent quarter AstraZeneca PLC reported earnings per share of $0.96.
Enterprise value:
264.4B
EV / Invested capital:
--
Price / LTM sales:
4.45x
EV / EBIT:
25.34x
EV / Revenue:
4.89x
PEG ratio (5yr expected):
1.93x
EV / Free cash flow:
36.34x
Price / Operating cash flow:
33.09x
Enterprise value / EBITDA:
17.06x
Gross Profit (TTM):
$43.9B
Return On Assets:
6.77%
Net Income Margin (TTM):
13.01%
Return On Equity:
17.77%
Return On Invested Capital:
9.88%
Operating Margin:
13.67%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $44.4B | $45.8B | $54.1B | $12B | $14.9B | |
| Gross Profit | $32B | $37.5B | $43.9B | $9.7B | $12.2B | |
| Operating Income | $4.6B | $8B | $10B | $1.2B | $2B | |
| EBITDA | $9.1B | $13.5B | $15.5B | $2.2B | $2.8B | |
| Diluted EPS | $2.11 | $3.83 | $4.51 | $0.62 | $0.96 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $19.5B | $26.2B | $22.6B | -- | $25.8B | |
| Total Assets | $66.7B | $105.4B | $96.5B | -- | $104B | |
| Current Liabilities | $20.3B | $22.6B | $26.3B | -- | $27.9B | |
| Total Liabilities | $51.1B | $66.1B | $59.4B | -- | $63.2B | |
| Total Equity | $15.6B | $39.3B | $37.1B | -- | $40.9B | |
| Total Debt | $19.7B | $29.8B | $28.2B | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $9.8B | $10.3B | $11.9B | $2.4B | $2.9B | |
| Cash From Investing | -$3B | -$4.1B | -$8B | -$1.1B | -$1.2B | |
| Cash From Financing | -$6.8B | -$6.6B | -$4B | -$291M | -$671M | |
| Free Cash Flow | $7.2B | $6.6B | $7.3B | $1.4B | $2B | |
AZNCF
Sector
Market Cap
$239.1B
$36.4M
Price % of 52-Week High
88.13%
45.1%
Dividend Yield
2.01%
0%
Shareholder Yield
5.03%
-0.74%
1-Year Price Total Return
15.63%
-39.83%
Beta (5-Year)
0.405
0.773
Dividend yield:
2.01%
Annualized payout:
$2.96
Payout ratio:
65.8%
Growth streak:
1 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$151.94
200-day SMA
Buy
Level
$148.96
Bollinger Bands (100)
Buy
Level
129.93 - 148.19
Chaikin Money Flow
Sell
Level
-1.3M
20-day SMA
Buy
Level
$149.06
Relative Strength Index (RSI14)
Buy
Level
57.69
ADX Line
Buy
Level
29.45
Williams %R
Neutral
Level
-26.5382
50-day SMA
Buy
Level
$140.77
MACD (12, 26)
Buy
Level
3.36
25-day Aroon Oscillator
Buy
Level
68
On Balance Volume
Sell
Level
-605.2K
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.782)
Sell
CA Score
(Annual)
Level (-0.3095)
Buy
Beneish M-Score
(Annual)
Level (-2.2404)
--
Momentum Score
Level (--)
Buy
Ohlson Score
Level (-1.1101)
Buy
Piotroski F Score
(Annual)
Level (8)
--
Quality Ratio Score
Level (--)
Buy
Fundamental Score
Level (8)
Revenue Forecast
Earnings per Share Forecast
Company Profile
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its sales.
Stock Forecast FAQ
In the current month, AZNCF has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The AZNCF average analyst price target in the past 3 months is --.
-
Where Will AstraZeneca PLC Stock Be In 1 Year?
According to analysts, the consensus estimate is that AstraZeneca PLC share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About AstraZeneca PLC?
Analysts are divided on their view about AstraZeneca PLC share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that AstraZeneca PLC is a Sell and believe this share price will rise from its current level to --.
-
What Is AstraZeneca PLC's Price Target?
The price target for AstraZeneca PLC over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is AZNCF A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for AstraZeneca PLC is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of AZNCF?
You can purchase shares of AstraZeneca PLC via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase AstraZeneca PLC shares.
-
What Is The AstraZeneca PLC Share Price Today?
AstraZeneca PLC was last trading at $149.40 per share. This represents the most recent stock quote for AstraZeneca PLC. Yesterday, AstraZeneca PLC closed at $154.22 per share.
-
How To Buy AstraZeneca PLC Stock Online?
In order to purchase AstraZeneca PLC stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Does Intel Stock Have Room to Grow?
Intel Corporation (NASDAQ:INTC)’s recent innovations, Xeon 6 SoC and Xeon®…
Is Walmart the Largest Retailer in the World?
For many years, Walmart (NYSE:WMT) has been the world’s largest…
Stock Ideas
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 36x
Sell
44
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Sell
45
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Sell
50
GH alert for Mar 12
Guardant Health [GH] is up 1.1% over the past day.
Sell
44
TER alert for Mar 12
Teradyne [TER] is down 0.36% over the past day.
Buy
57
LMB alert for Mar 12
Limbach Holdings [LMB] is down 4.39% over the past day.
